Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at BTIG Research

Key Points

• BTIG Research raised its price target to $100 (from $98) and keeps a "buy" rating, implying roughly a 25.48% upside from the prior close.
• Q1 results beat expectations: EPS $0.78 versus $0.73 consensus and revenue of about $1.65B (up ~16.7% YoY), with FY‑2026 EPS guidance of $2.95–$3.05.
• The stock traded down ~2.3% and insiders sold 86,058 shares (~$7.12M) in the last 90 days, a potential near‑term headwind despite heavy institutional ownership and a "Moderate Buy" analyst consensus.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price target raised by investment analysts at BTIG Research from $98.00 to $100.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. BTIG Research's target price points to a potential upside of 25.48% from the stock's previous close.

A number of other brokerages have also recently issued reports on EW. Wolfe Research raised shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a report on Wednesday, April 1st. UBS Group reaffirmed a "neutral" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the company a "hold" rating in a report on Wednesday, February 11th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an "outperform" rating in a report on Monday, April 13th. Finally, Evercore reaffirmed an "outperform" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $95.48.

Edwards Lifesciences Trading Down 2.3%

Shares of Edwards Lifesciences stock opened at $79.69 on Friday. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.95 billion, a PE ratio of 43.55, a price-to-earnings-growth ratio of 2.12 and a beta of 0.95. The company has a 50-day moving average of $81.54 and a two-hundred day moving average of $82.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.60 billion. During the same period last year, the company posted $0.64 earnings per share. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences will post 2.96 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares of the company's stock, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 86,058 shares of company stock valued at $7,118,636 in the last ninety days. Corporate insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. State Street Corp grew its stake in Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the period. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock worth $1,857,934,000 after acquiring an additional 989,533 shares during the period. Bank of New York Mellon Corp grew its stake in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Finally, Jennison Associates LLC grew its stake in Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 top-line beat and strong surgical product demand—Revenue rose ~16.7% YoY to about $1.65B, led by robust demand for artificial/transcatheter heart valves, which analysts flagged as the quarter’s standout driver. Read More.
• Positive Sentiment: Profitability and cash flow improvement—The company reported better-than-expected quarterly EPS per several outlets and showed improved operating profit and operating cash flow, supporting margins and longer-term earnings power. Read More.
• Neutral Sentiment: Guidance mostly in line but with range risk—Q2 EPS guidance of $0.70–$0.76 and FY 2026 EPS of $2.95–$3.05 are roughly around consensus but leave room for variance, which can limit upside if execution slips. Read More.
• Neutral Sentiment: Analyst positioning remains constructive—Multiple buy/overweight ratings and a median 12-month target near $98 point to continued analyst confidence, which can support the stock if results remain steady. Read More.
• Negative Sentiment: Insider selling and potential profit-taking—Recent notable insider sales and the large post-earnings run-up increase the risk of near-term selling pressure. Read More.
• Negative Sentiment: Mixed datapoints and market reaction—Although headlines emphasized a beat, some outlets highlighted differing EPS metrics and the stock’s reversal from its post-earnings pop, suggesting investors are parsing nuances rather than celebrating a clear clean beat. Read More.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.